Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV randomized double-blind placebo-controlled trial of Mezym F in pancreatic exocrine insufficiency due to chronic pancreatitis
2005-000562-38Phase 4Terminated
- Sponsor
- Berlin-Chemie AG
- Start
- Sep 2005
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in exocrine pancreatic insufficiency (EPI) comparing Mezym F with Placebo (2 arms). Primary endpoints: Cumulative 13C exhalation after 6 hours and Maximum 13C exhalation within 8 hours. Started Sep 2005; status: terminated.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2005-000562-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000562-38.